HK1208464A1 - Amorphous salt of a macrocyclic inhibitor of hcv hcv - Google Patents

Amorphous salt of a macrocyclic inhibitor of hcv hcv

Info

Publication number: HK1208464A1
Authority: HK; Hong Kong
Prior art keywords: hcv; amorphous salt; macrocyclic inhibitor; macrocyclic; inhibitor
Prior art date: 2009-02-27

Application number

HK15109245.7A

Other languages

Chinese (zh)

Inventor

Peter Jozef Maria Van Remoortere

Roger Petrus Gerebern Vandecruys

Kock Herman De

Original Assignee

Ortho Mcneil Janssen Pharm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-27

Filing date

2015-09-21

Publication date

2016-03-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1208464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-09-21 Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm

2016-03-04 Publication of HK1208464A1 publication Critical patent/HK1208464A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

HK15109245.7A 2009-02-27 2015-09-21 Amorphous salt of a macrocyclic inhibitor of hcv hcv HK1208464A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09153964		2009-02-27

Publications (1)

Publication Number	Publication Date
HK1208464A1 true HK1208464A1 (en)	2016-03-04

Family

ID=40756982

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK12106950.1A HK1166315A1 (en)	2009-02-27	2012-07-16	Amorphous salt of a macrocyclic inhibitor of hcv hcv
HK15109245.7A HK1208464A1 (en)	2009-02-27	2015-09-21	Amorphous salt of a macrocyclic inhibitor of hcv hcv

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK12106950.1A HK1166315A1 (en)	2009-02-27	2012-07-16	Amorphous salt of a macrocyclic inhibitor of hcv hcv

Country Status (26)

Country	Link
US (2)	US9321758B2 (en)
EP (2)	EP3150596A1 (en)
JP (2)	JP5711672B2 (en)
KR (2)	KR101868412B1 (en)
CN (2)	CN102356080B (en)
AU (1)	AU2010219160B2 (en)
BR (1)	BRPI1008918A2 (en)
CA (2)	CA2753667C (en)
CY (1)	CY1119121T1 (en)
DK (1)	DK2401272T3 (en)
ES (1)	ES2616603T3 (en)
HK (2)	HK1166315A1 (en)
HR (1)	HRP20170214T1 (en)
HU (1)	HUE031738T2 (en)
IL (2)	IL214398A0 (en)
LT (1)	LT2401272T (en)
MX (1)	MX340792B (en)
NZ (1)	NZ594403A (en)
PL (1)	PL2401272T3 (en)
PT (1)	PT2401272T (en)
RU (1)	RU2536868C2 (en)
SG (2)	SG2014008981A (en)
SI (1)	SI2401272T1 (en)
SM (2)	SMT201700121T1 (en)
WO (1)	WO2010097229A2 (en)
ZA (1)	ZA201106303B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI454476B (en)	2008-07-08	2014-10-01	Tibotec Pharm Ltd	Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
RU2536868C2 (en) *	2009-02-27	2014-12-27	Орто-Макнейл-Янссен Фармасьютикалз Инк	Amorphous salt of macrocyclic hcv inhibitor
US9034832B2 (en) *	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
EP2907505A3 (en) *	2011-12-29	2015-12-30	Abbvie Inc.	Solid compositions comprising an HCV inhibitor
BR112015003913A2 (en) *	2012-08-31	2017-07-04	Janssen Pharmaceuticals Inc	combination of hcv macrocyclic protease inhibitor, non-nucleoside hcv inhibitor and ritonavir
HUE047777T2 (en)	2013-01-31	2020-05-28	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
BR112015021692A2 (en) *	2013-03-15	2017-07-18	Boehringer Ingelheim Int	amorphous state solid oral hcv inhibitor dosage formulation
PT3650014T (en)	2013-08-27	2021-12-27	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
WO2015109925A1 (en) *	2014-01-21	2015-07-30	杭州普晒医药科技有限公司	Crystalline form of hepatitis c drug and preparation method, pharmaceutical composition and use thereof
CN105308043B (en) *	2014-05-29	2018-01-30	杭州普晒医药科技有限公司	Crystal formation of hepatitis C medicine and preparation method thereof, its pharmaceutical composition and purposes
WO2016054240A1 (en) *	2014-09-30	2016-04-07	Sean Dalziel	Fixed dose combinations for the treatment of viral diseases
CZ2015220A3 (en) *	2015-03-27	2016-10-05	Zentiva, K.S.	Amorphous salt of hepatitis C virus macrocyclic inhibitor
WO2016177625A1 (en)	2015-05-04	2016-11-10	Sandoz Ag	Amorphous simeprevir potassium
WO2017017604A1 (en)	2015-07-27	2017-02-02	Lupin Limited	Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060083784A1 (en) *	2002-08-07	2006-04-20	Smithkline Beecham Corporation	Amorphous pharmaceutical compositions
SI1680137T1 (en) *	2003-10-14	2013-02-28	F. Hoffmann-La Roche Ltd.	Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication
NZ548739A (en)	2004-01-30	2010-10-29	Medivir Ab	HCV NS-3 Serine protease inhibitors
CA2557256A1 (en) *	2004-02-24	2005-09-01	Siegfried Generics International Ag	Pharmacologically acceptable salts of clopidogrel
UA91677C2 (en) *	2004-03-30	2010-08-25	Интермюн, Инк.	Macrocyclic compounds as inhibitors of hcv replication
JP4950026B2 (en)	2004-03-30	2012-06-13	インターミューン・インコーポレーテッド	Macrocyclic compounds as viral replication inhibitors
EP1831171A4 (en) *	2004-11-19	2010-09-15	Matrix Lab Ltd	Process for the preparation of novel amorphous montelukast sodium
PE20070211A1 (en) *	2005-07-29	2007-05-12	Medivir Ab	MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
PE20070343A1 (en)	2005-07-29	2007-05-12	Medivir Ab	MACRO CYCLIC INHIBITORS OF HEPATITIS C VIRUS
JP2008115173A (en) *	2006-10-13	2008-05-22	Eisai R & D Management Co Ltd	Salts, those crystals, and amorphous objects of sulfinyl benzimidazole compounds
US8399434B2 (en)	2006-11-08	2013-03-19	Duke University	Method of activation of oxazaphosphorines
JP5523110B2 (en) *	2007-02-01	2014-06-18	ヤンセン・アールアンドデイ・アイルランド	Polymorphic forms of macrocyclic inhibitors of HCV
PT2121674E (en) *	2007-02-01	2010-09-03	Tibotec Pharm Ltd	Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
CN101842356A (en) *	2007-08-29	2010-09-22	辉瑞产品公司	Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same
RU2536868C2 (en) *	2009-02-27	2014-12-27	Орто-Макнейл-Янссен Фармасьютикалз Инк	Amorphous salt of macrocyclic hcv inhibitor

2010
- 2010-02-26 RU RU2011139325/04A patent/RU2536868C2/en not_active IP Right Cessation
- 2010-02-26 NZ NZ594403A patent/NZ594403A/en not_active IP Right Cessation
- 2010-02-26 SM SM20170121T patent/SMT201700121T1/en unknown
- 2010-02-26 LT LTEP10706539.3T patent/LT2401272T/en unknown
- 2010-02-26 CA CA2753667A patent/CA2753667C/en not_active Expired - Fee Related
- 2010-02-26 DK DK10706539.3T patent/DK2401272T3/en active
- 2010-02-26 PT PT107065393T patent/PT2401272T/en unknown
- 2010-02-26 US US13/202,166 patent/US9321758B2/en not_active Expired - Fee Related
- 2010-02-26 EP EP16195560.4A patent/EP3150596A1/en not_active Withdrawn
- 2010-02-26 CN CN201080009908.9A patent/CN102356080B/en not_active Expired - Fee Related
- 2010-02-26 SG SG2014008981A patent/SG2014008981A/en unknown
- 2010-02-26 CN CN201410616884.3A patent/CN104478868A/en active Pending
- 2010-02-26 BR BRPI1008918A patent/BRPI1008918A2/en not_active Application Discontinuation
- 2010-02-26 SG SG2011059862A patent/SG173772A1/en unknown
- 2010-02-26 ES ES10706539.3T patent/ES2616603T3/en active Active
- 2010-02-26 HU HUE10706539A patent/HUE031738T2/en unknown
- 2010-02-26 MX MX2011008999A patent/MX340792B/en active IP Right Grant
- 2010-02-26 KR KR1020177005726A patent/KR101868412B1/en active IP Right Grant
- 2010-02-26 SI SI201031402A patent/SI2401272T1/en unknown
- 2010-02-26 AU AU2010219160A patent/AU2010219160B2/en not_active Ceased
- 2010-02-26 PL PL10706539T patent/PL2401272T3/en unknown
- 2010-02-26 WO PCT/EP2010/001197 patent/WO2010097229A2/en active Application Filing
- 2010-02-26 JP JP2011551440A patent/JP5711672B2/en not_active Expired - Fee Related
- 2010-02-26 KR KR1020117022464A patent/KR101713066B1/en active IP Right Grant
- 2010-02-26 CA CA2898529A patent/CA2898529C/en not_active Expired - Fee Related
- 2010-02-26 EP EP10706539.3A patent/EP2401272B1/en active Active
2011
- 2011-08-02 IL IL214398A patent/IL214398A0/en unknown
- 2011-08-26 ZA ZA2011/06303A patent/ZA201106303B/en unknown
2012
- 2012-07-16 HK HK12106950.1A patent/HK1166315A1/en not_active IP Right Cessation
2015
- 2015-03-06 JP JP2015044264A patent/JP6214584B2/en not_active Expired - Fee Related
- 2015-09-21 HK HK15109245.7A patent/HK1208464A1/en unknown
- 2015-12-22 IL IL243058A patent/IL243058A0/en unknown
2016
- 2016-03-08 US US15/063,821 patent/US20160251345A1/en not_active Abandoned
2017
- 2017-02-08 HR HRP20170214TT patent/HRP20170214T1/en unknown
- 2017-02-22 SM SM201700121T patent/SMT201700121B/en unknown
- 2017-02-22 CY CY20171100246T patent/CY1119121T1/en unknown

Also Published As

Publication number	Publication date
IL214398A0 (en)	2011-09-27
SI2401272T1 (en)	2017-04-26
RU2536868C2 (en)	2014-12-27
SG2014008981A (en)	2014-04-28
CN102356080A (en)	2012-02-15
SMT201700121T1 (en)	2017-03-08
KR101713066B1 (en)	2017-03-07
CA2898529C (en)	2017-10-17
AU2010219160A1 (en)	2011-08-25
KR20110123273A (en)	2011-11-14
SG173772A1 (en)	2011-09-29
PL2401272T3 (en)	2017-06-30
ES2616603T3 (en)	2017-06-13
SMT201700121B (en)	2017-03-08
CA2753667A1 (en)	2010-09-02
NZ594403A (en)	2013-07-26
MX340792B (en)	2016-07-25
DK2401272T3 (en)	2017-02-27
AU2010219160B2 (en)	2015-12-10
HUE031738T2 (en)	2017-07-28
ZA201106303B (en)	2013-02-27
CN102356080B (en)	2015-04-29
CA2898529A1 (en)	2010-09-02
MX2011008999A (en)	2011-09-26
EP2401272B1 (en)	2017-01-11
EP2401272A2 (en)	2012-01-04
CA2753667C (en)	2015-11-17
HK1166315A1 (en)	2012-10-26
JP6214584B2 (en)	2017-10-18
EP3150596A1 (en)	2017-04-05
IL243058A0 (en)	2016-02-29
WO2010097229A2 (en)	2010-09-02
US20110306634A1 (en)	2011-12-15
JP2012519158A (en)	2012-08-23
JP5711672B2 (en)	2015-05-07
CY1119121T1 (en)	2018-02-14
CN104478868A (en)	2015-04-01
BRPI1008918A2 (en)	2016-03-15
KR101868412B1 (en)	2018-06-18
US20160251345A1 (en)	2016-09-01
HRP20170214T1 (en)	2017-04-07
LT2401272T (en)	2017-03-27
JP2015143240A (en)	2015-08-06
WO2010097229A3 (en)	2010-11-11
US9321758B2 (en)	2016-04-26
PT2401272T (en)	2017-02-28
RU2011139325A (en)	2013-04-10
KR20170026660A (en)	2017-03-08

Publication	Publication Date	Title
HRP20170214T1 (en)	2017-04-07	Amorphous salt of a macrocyclic inhibitor of hcv
HUS000511I2 (en)	2021-03-29	Gilteritinib or a salt thereof
HK1254977A1 (en)	2019-08-02	Crystalline form of sofosbuvir
EP2410841A4 (en)	2012-10-24	Substituted bicyclic hcv inhibitors
IL221198A0 (en)	2012-10-31	Crystalline salts of a potent hcv inhibitor
IL216648A0 (en)	2012-03-01	Crystalline forms of febuxostat
PT2611779T (en)	2016-11-21	Crystalline forms of a factor xa inhibitor
AP3079A (en)	2015-01-31	A slush
IL215315A0 (en)	2011-12-29	Solid state forms of sitagliptin salts
AP3169A (en)	2015-03-31	A method of improved positioning
SG10201408584UA (en)	2015-02-27	Crystalline Methylthionium Chloride Hydrates
EP2504343A4 (en)	2013-04-17	Hepatitis c inhibitor compounds
PL2333462T3 (en)	2017-06-30	Three forms of ice from a single well
AP2013006733A0 (en)	2013-02-28	Solid state forms of a potent HCV inhibitor
HK1169314A1 (en)	2013-01-25	Use of delta-tocopheryl-carbohydrate as a depigmenting agent --
GB2458027B (en)	2010-01-20	A method of selection
GB0904499D0 (en)	2009-04-29	A set of parts
GB0903651D0 (en)	2009-04-15	Inhibitors of glyoxalase
GB0919237D0 (en)	2009-12-16	Improvements of a device
GB0902782D0 (en)	2009-04-08	Disposal of metal salts
SI2398784T1 (en)	2013-02-28	Crystalline forms of febuxostat
PH32009000313S1 (en)	2009-11-16	Portion of a toothbrush
PH32009000314S1 (en)	2010-05-24	Portion of a toothbrush
PH32009000714S1 (en)	2010-07-19	Portion of a toothbrush
PH32009000713S1 (en)	2010-08-23	Portion of a toothbrush